Eli Lilly: signs licensing deal with Precision BioSciences
(CercleFinance.com) - Eli Lilly has announced an exclusive license deal with Precision BioSciences that will allow the company to utilize its genome editing platform for the research and development of therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy.
Under the terms of the partnership, Precision will receive 100 million dollars cash upfront and an equity investment 35 million dollars, also being eligible to potential milestones up to 420 million dollars per product, as well as tiered royalties.
Genome editing enables precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source.
Yesterday, Lilly announced that the US Food and Drug Administration (FDA) issued an emergency use authorization for baricitinib to be used in combination in combination with remdesivir in hospitalized patients with Covid-19 needing oxygen.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Under the terms of the partnership, Precision will receive 100 million dollars cash upfront and an equity investment 35 million dollars, also being eligible to potential milestones up to 420 million dollars per product, as well as tiered royalties.
Genome editing enables precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source.
Yesterday, Lilly announced that the US Food and Drug Administration (FDA) issued an emergency use authorization for baricitinib to be used in combination in combination with remdesivir in hospitalized patients with Covid-19 needing oxygen.
Copyright (c) 2020 CercleFinance.com. All rights reserved.